Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: introducing a parameter quantifying CD33 expression on CD34+ cells

Myelodysplastic syndromes (MDS) have been diagnosed based on a combination of clinical history, morphologic features of myeloid cells, cytogenetic data, and ruling out other diseases [1 –3]. An increase in blasts or MDS-related cytogenetic abnormalities is an objective finding for straightforward diagnosis. However, 50% or more of low-grade MDS (MDS without blast excess) patients lack cytogenetic abnormalities [4]. Furthermore, dysplastic myeloid cells do not in themselves establ ish a diagnosis. There are conditions other than MDS which can induce myeloid dysplasia (e.g., deficiencies of vitamin B12 and folate, viral infections, and exposure to antibiotics, chemotherapeutic agents, ethanol, benzene, or lead).

Source: Leukemia Research - July 10, 2018 Category: Hematology Authors: Kiyoyuki Ogata, Kazuma Sei, Leonie Saft, Naoya Kawahara, Matteo G Della Porta, Nicolas Chapuis, Yumi Yamamoto Source Type: research